- Home
- DTF vs ALGS Comparison
DTF vs ALGS Comparison
Compare DTF & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTF
- ALGS
- Stock Information
- Founded
- DTF 1991
- ALGS 2018
- Country
- DTF United States
- ALGS United States
- Employees
- DTF N/A
- ALGS N/A
- Industry
- DTF Investment Managers
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- DTF Finance
- ALGS Health Care
- Exchange
- DTF Nasdaq
- ALGS Nasdaq
- Market Cap
- DTF 79.8M
- ALGS 64.8M
- IPO Year
- DTF N/A
- ALGS 2020
- Fundamental
- Price
- DTF $11.28
- ALGS $7.21
- Analyst Decision
- DTF
- ALGS Strong Buy
- Analyst Count
- DTF 0
- ALGS 2
- Target Price
- DTF N/A
- ALGS $60.00
- AVG Volume (30 Days)
- DTF 21.1K
- ALGS 99.6K
- Earning Date
- DTF 01-01-0001
- ALGS 11-06-2025
- Dividend Yield
- DTF 3.64%
- ALGS N/A
- EPS Growth
- DTF N/A
- ALGS N/A
- EPS
- DTF 0.44
- ALGS N/A
- Revenue
- DTF N/A
- ALGS $3,174,000.00
- Revenue This Year
- DTF N/A
- ALGS N/A
- Revenue Next Year
- DTF N/A
- ALGS N/A
- P/E Ratio
- DTF $24.34
- ALGS N/A
- Revenue Growth
- DTF N/A
- ALGS N/A
- 52 Week Low
- DTF $10.29
- ALGS $3.76
- 52 Week High
- DTF $11.19
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- DTF 39.52
- ALGS 28.33
- Support Level
- DTF $11.35
- ALGS $9.25
- Resistance Level
- DTF $11.41
- ALGS $8.76
- Average True Range (ATR)
- DTF 0.08
- ALGS 0.77
- MACD
- DTF -0.01
- ALGS -0.30
- Stochastic Oscillator
- DTF 0.00
- ALGS 2.68
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.